Antithrombotic Therapy for Atrial Fibrillation
John J. You(McMaster University), Gregory Y.H. Lip(University of Liverpool), Daniel E. Singer(Harvard University), Alan S. Go(Kaiser Permanente), Patricia Howard(University of Kansas Medical Center), Margaret C. Fang(University of California, San Francisco), Warren J. Manning(Harvard University Press), Elaine M. Hylek(Boston University), Sam Schulman(Hamilton General Hospital), Jonathan L. Halperin(Greenville College), Michael Hughes(Decision Research), Mark H. Eckman(University of Cincinnati), Frederick A. Spencer(McMaster University), Deirdre A. Lane(University of Birmingham)
Cited by 919
Related Papers
Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization
|New England Journal of Medicine|2004|11.4k
Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation
|New England Journal of Medicine|2011|9.4k
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
|Stroke|2014|5.2k
Heart Disease and Stroke Statistics—2013 Update
|Circulation|2012|5.2k
Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients
|Journal of Thrombosis and Haemostasis|2005|4.9k